Category: JPM
-
Breaking down JPM 2026: the mood, the big interviews — and all the AI billboards
Breaking down JPM 2026: the mood, the big interviews — and all the AI billboards In last week’s STATus Report episode, we heard from STAT reporters Allison DeAngelis and Damian Garde, who shared what they would be keeping an eye out for at this year’s J.P. Morgan Healthcare Conference. Top of mind was predicting this…
-
STAT+: On Day 4 of JPM, a chat with Regeneron’s George Yancopoulos, an IPO forecast, and all eyes on J&J
STAT+: On Day 4 of JPM, a chat with Regeneron’s George Yancopoulos, an IPO forecast, and all eyes on J&J This is the online version of The Readout, STAT’s flagship biotech newsletter. Sign up to get it in your inbox. We have made it! And so have you. This is Adam, Elaine, Matt, and Allison preparing to sign…
-
STAT+: On Day 3 of JPM, pharma threads a needle with the White House, and Novo Nordisk has an eye on M&A
STAT+: On Day 3 of JPM, pharma threads a needle with the White House, and Novo Nordisk has an eye on M&A This is the online version of The Readout, STAT’s flagship biotech newsletter. Sign up to get it in your inbox. It’s Day 3 of JPM and all of us — Matt, Elaine, Adam, and Allison — are…
-
STAT+: Secretive Project Prometheus takes VC Bob Nelsen beyond just health care
STAT+: Secretive Project Prometheus takes VC Bob Nelsen beyond just health care SAN FRANCISCO — Venture capitalist Bob Nelsen believes his latest project will be “one of the most important companies in the world.” But, unusually for the longtime biotech investor, it’s not strictly in health care. Nelsen has been quietly working on a new…
-
STAT+: Watch: At JPM, former drug regulator Richard Pazdur rings the alarm about politics at FDA
STAT+: Watch: At JPM, former drug regulator Richard Pazdur rings the alarm about politics at FDA Richard Pazdur, a veteran regulator at the Food and Drug Administration until last month, joined STAT in San Francisco on Monday evening to make his first public remarks about the circumstances leading up to his abrupt departure. At an…
-
STAT+: On Day 2 of JPM, Gilead lays outs it next test, a VC looks to raise funds, and one firm has FDA whiplash
STAT+: On Day 2 of JPM, Gilead lays outs it next test, a VC looks to raise funds, and one firm has FDA whiplash This is the online version of The Readout, STAT’s flagship biotech newsletter. Sign up to get it in your inbox. You’re back. We’re sort of back. It’s Day 2 of JPM and we’re…
-
STAT+: With a grin — and tight lips — Revolution Medicines’ CEO faces questions about acquisition
STAT+: With a grin — and tight lips — Revolution Medicines’ CEO faces questions about acquisition SAN FRANCISCO — Investors attending the J.P. Morgan Healthcare Conference packed themselves into a hotel meeting room Monday to hear Revolution Medicines CEO Mark Goldsmith explain why Merck — or some other pharma buyer — should pay $30 billion…
-
STAT+: On Day 1 of JPM, no blockbuster headlines, but biotech newsmakers still move markets
STAT+: On Day 1 of JPM, no blockbuster headlines, but biotech newsmakers still move markets This is the online version of The Readout, STAT’s flagship biotech newsletter. Sign up to get it in your inbox. Hello from sunny San Francisco, where #BiotechVibeWatch2026 has begun. This is Allison DeAngelis, joined here by STAT’s Adam Feuerstein, Matthew Herper, and…
-
STAT+: At JPM, doctors’ darling OpenEvidence says it’s pursuing ‘medical super-intelligence’
STAT+: At JPM, doctors’ darling OpenEvidence says it’s pursuing ‘medical super-intelligence’ OpenEvidence has rapidly become a household name among physicians, with a chatbot that answers their day-to-day clinical questions. Last year, it raised $200 million — twice — valuing the company at more than $6 billion. Its next reported round, yet to be confirmed, would…
-
STAT+: Alnylam charts ambitious five-year plan as sales of key drug miss expectations
STAT+: Alnylam charts ambitious five-year plan as sales of key drug miss expectations SAN FRANCISCO — On Sunday, Alnylam, the gene-silencing company that notched one gigantic accomplishment after another over the past five years, set out a plan for the next five years built on yet more innovation and growth. At the same time, it announced…
-
STAT+: Why the JP Morgan conference is important — but not make-or-break
STAT+: Why the JP Morgan conference is important — but not make-or-break This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. My advice for JPM week: chill SAN FRANCISCO — The super-sized gathering of the biopharma universe is important, but it’s…
-
STAT+: FDA puts off Stoke’s request for faster filing of severe epilepsy drug
STAT+: FDA puts off Stoke’s request for faster filing of severe epilepsy drug SAN FRANCISCO — Stoke Therapeutics and the Food and Drug Administration were unable to reach agreement on an expedited submission for the company’s severe epilepsy treatment, the company said Sunday. Following a meeting in December, the FDA did not shut the door…
-
JPM to bring more deals and happy CEOs
JPM to bring more deals and happy CEOs What news happened over the holidays? Why will pharma CEOs be greeted warmly in San Francisco next week? And who will buy Revolution Medicines? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast. We bring on former co-host…